Skip to main content
PHVS $31.60 -0.19%
PHVS · Pharvaris N.V.
Track PHVS — free
$31.60 -0.06 (-0.19%)
Market Cap
$2.24B
Shares
70.79M
Volume · Nov 20 218.81K Avg daily vol (3M) 755.25K
All webcasts

Conference · 2026-09-09

Pharvaris N.V. (PHVS) September 9, 2026 Conference Transcript

Concluded Sep 9, 2026 Audio replay
Sep 9, 2026 34:26 42 turns
Period
2026-09-09
Runtime
34:26
Sources
2 artifacts

Transcript & audio

34:26 Audio
Yanen Zhu Analyst — Wells Fargo

Great. Thanks, everyone, for being here. My name is Yanen Zhu, and I'm one of the biotech analysts here at Wells Fargo. It is my great pleasure to be joined by the management team of far various. And with me on stage is Bernd Modig, CEO of the company, Peng Lu, president of the company, and Wim Silverance, chief commercial officer. of the company. Thank you all for being here.

Yeah, thank you for hosting us.

Yanen Zhu Analyst — Wells Fargo

Wonderful, wonderful. So, obviously, you just recently reported very important phase three data for the prophylactic set, your products in that setting. But to kick us off, could you give a overview of the company, and maybe segue into the data that you presented?

Yeah, so our journey actually started 10 years ago, and four months to be exact, when we set out to develop Decryctiband, and I guess we, myself and also my co-founder in the AGE space, came in first 23 years ago with the company that developed Decryctiband, and we identified or saw a huge unmet need for an oral therapy option for people living with AGE. So that's our vision then to come up with such a molecule and then that's when we started and then the scientific base of the company really focuses on the deeper understanding of the bradykinin pathway and the B2 receptor and so we are proud to say that to our knowledge we have the first and only orally available B2 receptor antagonist to correct about it. And the nice thing about that molecule is that compared to catabat, it has a significantly longer half-life, which makes it suitable both for prophylaxis and on-demand development. So we set out to develop, with that one, a same active ingredient two product, one for on-demand and one for prophylaxis. And now, 10 years later, we... Yesterday, actually, we saw we have the data for the prophylactic phase three study, and also, as you know, in December last year, we also had the phase three data for the on-demand formulation, which isn't currently under review by the FDA, with the PDUFA date in April. So, with the data that we saw yesterday... We're incredibly excited to really see that that vision that we had 10 years ago is coming closer to fruition and to be able to fill that unmet need in this therapeutic space. And with the data that we saw, we are up there together with the existing therapies in the longer acting injectables, but with the benefit of an oral option. And so that differentiates us from that perspective, and also the molecule itself also has, because of the modality and also the treatment regimen we want daily, and the flexibility of... Being able to start the therapy, having the activity kick in very quickly, and also, of course, relatively short washout, so that means if you discontinue the treatment or if you want to transfer over to on demand or if you want to have a medical procedure where you can't have drugs, so that gives the concept of control is really a key factor that also differentiates us in this space. So it's a high efficacy, tolerability, and the oral convenience. And so that is, in our view, then provides the benefit of maximum control for somebody living with an HAE condition.

Yanen Zhu Analyst — Wells Fargo

Great, great. Yeah, yeah. I do think the efficacy is notable. I don't know if you yourself is even a little surprised by the efficacy, because I know you already have very confident, you know, high confidence about the efficacy, but still, the number is right there with the injectables, right? Can you just maybe talk about, you know, how do you see, you know, when you saw the results, you know, what do you think about the efficacy? And maybe comment also on the placebo arm also a little bit for- Yeah,

so I mean, the efficacy, I mean, first of all, also, we're also very excited to see the replication or even potentially better than the phase two data that we saw. So in a phase three study, and in spite of also the increased footprint of the study, more size, more diverse patients, The patient population, et cetera. So we were extremely pleased with that level of efficacy and if you really compare with the patient population type 1 and type 2. of hereditary angioedema, which is what is covered by the other injectables. We ride up there with 87% attack reduction. The primary endpoint in the overall study was 83% because we also included a few patients with normal C1. And so the overall, which was included in the primary endpoint, but the comparison directly apples to apples to the type 1 and type 2 is 87% as we also Yeah, sure.

Peng Lu Other

Actually, from the placebo part, maybe someone viewed that actually the placebo, actually, if we look at the placebo arm, the attack rate is around 2.6 attack per month compared to other HE pivotal trials, actually very well within the range between 2 and 2.3 other pivotal trials. There's a further, as I mentioned, that confirmed that actually this trial conducted very well, even though I have to say that this is the first, maybe, the pivotal trial covered all the six continentals that we do that have patients from not only that in North America and Europe, right, as we did for phase two, we also covered the patients from Asian Pacific, Latin American countries, and also South Africa. That's why the patient advocacy group are very excited to show really we covered high medical need globally.

Yanen Zhu Analyst — Wells Fargo

Great, yeah, that is indeed quite an achievement, so congrats on that data. There are some interest after you present the data, some interest in learning more about some liver enzyme elevation observations from the study, so I wonder if we can take this opportunity to look more closer to those findings. Could you, you know, maybe review what were the liver enzyme observations and what are the circumstances of those findings?

Peng Lu Other

Yeah, actually, I can take over here that as we shared that, you know, in the, you know, the public presentation there, that within this trial, we indeed that have the two patients with the level 2, the liver enzyme elevation. We shared both cases, you know, the hepatic enzyme, you know, around slightly above five-fold from the upper limit. So as mentioned, that for HE patients, due to some patients, the long-term androgen use and also due to disease themselves, patients have quite a fragile liver. That's why almost from that most, almost every HE pivotal trial, that there is more or less some liver enzyme elevation observed. Come to these two cases, you know, that we shared that there is no any symptoms reported within these two cases, and also there is no bilirubin elevation observed, also some co-founding factors, you know, that followed with these two patients, one with historic fatty liver, the other with long-term androgen use. So really, they follow each individual investigator's assessment. One investigator feels more cautious. That's why she discontinued the treatment for one patient during the study, but the other PI evaluates to continue the treatment for the patient, and the patient completes the study. So that's pretty much these two cases, and from that compared to other prophy that currently approved prophy trial, we feel for the liver enzyme elevation and for the, you know, the cases here are quite comparable to other trials.

Yanen Zhu Analyst — Wells Fargo

Got it. Yeah. Could you touch on? ...fixing some microphone issues here. Fixing the microphone here real quick as me. Okay. Great, great. Yeah, so you touched upon the last point is regarding other approved therapies and how there might also be liver enzyme findings. Could you elaborate a little more on that?

Peng Lu Other

Yeah, actually, as I mentioned, that for example, that most now that, you know, center of care for Lendelamab, that if we look at their label, there is also that, you know, that the lab abnormality for hepatic enzyme section is shown also that a few cases, liver enzyme elevations that are reported there, and also that one patient discontinued the treatment due to the liver enzyme elevation. Similar cases for Ordello, another oral treatment, and also for the Donna Dorsen, that is the latest approved treatment there.

Yanen Zhu Analyst — Wells Fargo

Got it. Yeah, very helpful. So overall, what's your expectation of the implication for your finding in terms of whether there could incur any monitoring requirement? And also, in the real world and commercial setting, whether that could cause any change in behavior.

Peng Lu Other

Yeah, for this one, we always want to wait the safety assessment until the NDA filing until approval, right? Because this will integrate Chapter 3, Chapter 4, the long-term safety assessment there. But based on the current Chapter 3 data, we feel it's quite, as mentioned, waiting the range for other profit treatments. We don't expect that medical monitoring there, and we expect the label may be very comparable to other profit treatments. And while we discuss with the QP leaders, they fully understand the disease set there, and they fully aware that a potentially co-founding factor, no matter for disease itself or the long-term androgen use, as we discussed.

Yanen Zhu Analyst — Wells Fargo

Right, right. Yeah, those make a lot of sense. May I follow up by asking when might we see the combined data set for safety, And perhaps also in terms of publishing the study result, could you comment on those timelines?

Peng Lu Other

Excellent question. Currently, our Open Label Extension Study, Chapter 4 study, is still ongoing because we just actually get the top line readout from the Chapter 3 just unblended. Then the team need to figure out how many patients, the status, the treatment, the duration in the Chapter 4. So, currently, we don't give the clear guidance regarding the one-chapter data, the one-year safety data package will be available, but soon, once available, that we will, maybe once that we... Get the data cutoff for one year safety, then we wrap up the package, and we will consider that publishing the data, presents the data in the medical conference.

Yanen Zhu Analyst — Wells Fargo

Got it, got it, got it. In terms of patient rolling over from the main study to the long-term follow-up, can you comment on the rate of rollover?

Peng Lu Other

Sure. As illustrated from the study, altogether 83, the patients complete the study, and 80 out of 83 patients roll over to the chapter 4, open labor extension study.

Yanen Zhu Analyst — Wells Fargo

Got it. Very helpful. Can we talk about a timeline for filing and what are the gating items before you file?

Yeah, so the guidance for filing is in the first half of next year. And in addition to what Pong described on the safety package, we also are aiming to include data from the ongoing Create Drive and acquired Android Emo. And with the putting that together with the filing for the HAE filing and with the possibility of a subject to regulatory concurrence and approval with the broader label for bradykinin-mediated androdema. And so that the study is ongoing and it's on track, and we have guided also the top-line data from that study in Q1 of next year.

Yanen Zhu Analyst — Wells Fargo

Right. Yeah. Speaking of breadth of coverage, can you comment on the inclusion? Obviously, you touched on the inclusion of a normal C1-INH patient earlier. What's the significance of that?

Peng Lu Other

Yeah, I can comment later on. I will hand it over to Wim from the commercial side. And from the scientific part, as Bern mentioned, is that Ducridban is very unique because no matter approved treatments that are currently under development treatment for prophylaxis, they all target quite an upper stream of the pathway, either factor 12 pre-calocrine or calocrine. Therefore, they only can prevent attack depending on the plasma calicoin pathway. However, for a lot of HE patients, if it's not due to C1 deficiency, if it's a normal C1 inhibitor, there is maybe currently eight known genetic mutation and also a lot of patients with unknown genetic mutation. But canine can be produced either from plasma calicoin pathway type 1-2, It's also maybe tissue calicoin or plasma calicoin-independent pathway. Therefore, all the other treatment that will not be effective cannot help these patients, and Ducretibine, because we block the most downstream, right, the interaction between Bradkine and B2 receptor here, therefore, no matter which pathway, Ducretibine is expected to work. That's why we also include that normal C1 patients into our pivotal study, demonstrate for all the three patients, even though some variability there, it helped all three patients there. So therefore, we are very proud. These patient populations, there are still no effective treatment. We are able to help these patients.

And I think the commercial implication of that is that we anticipate in that segment, where there's a wide range of estimates in terms of prevalence, people talk between 15 and 25% of the type 1, type 2 population, we anticipate having a disproportionately higher share of those patients because of the fact that we do work at the level of the receptor rather than in the kidney pathway. And so that's important, obviously, commercially, to differentiate ourselves from other products in the market. And I think combining that with the acquired angiodema part of the label, we all of a sudden have a label that's the broadest of all prophylactic therapies. And so that becomes attractive for doctors, makes their lives simple. It might be attractive also for peers because the drug will work in a different area. So that's a pretty big advantage commercially.

Yanen Zhu Analyst — Wells Fargo

Got it, got it. This is a great opportunity to dive into the commercial opportunity. So I guess, how do you see the commercial launch go, pending approval? How do you see this launch go? Obviously, there are injectables, there are Oladeo and Auro, these options out there. Is this going to be a new patient, new to therapy only kind of launch or a switching launch? If it's a switching type launch, where do you see the switch come from?

Well, I think we got an amazing profile to really win in the prophylactic segments, And that's because of the ability to tackle three distinct segments. First of all, we have patients new to LTP, new to prophylaxis. What we've learned from the community is that if you can deliver injectable-like efficacy, which we've now shown, With the data, you become the de facto first-line therapy, first-line option for prophylaxis. With our efficacy and our tolerability profile, our anticipation is that the dropout rate from duocryctiband in prophylaxis will be very limited. As you probably know, Oladeo, the other oral, It's being used widely in new patients, but about 40% of the patients on Oladea drop out either for efficacy or for tolerability challenges. We don't have that issue. What that means is that you create what I call a pancake effect. Because if you can take every year the majority or a large part of the new patients to LTP, which range between 150 and 250 per year, you build up. Share in the overall market, and so that will really drive our leadership in the long term. That's the first segment. Secondly, thinking about your whole segment. Yes. Patients on Orlodeo that stayed on Orlodeo will feel better. They went from lots of attacks to much fewer attacks with Orlodeo. But if you look at real-world evidence, those patients still have a relatively high number of breakthrough attacks, talking between 6 to 12 per year. Therefore, for those patients who want an oral, it's actually a fairly easy switch to say, why don't I try an other oral that can offer a better efficacy? The beauty of Ducryptomant is that because of the PK, if you take the drug in the morning, technically in the afternoon, you have enough drug in your system to prevent the accident happening. After two, three days, you're in steady state. So patients don't take any risk and can really test that product. So that's why we believe, strongly believe, that the oral segment ultimately will be largely dominated by the quick demand. And then the third bucket are those patients that are on injectables. And while for sure there will be patients that will prefer to have an injectable, probably most likely a long-acting injectable when that will become available, But a lot of patients on Texiro or Endembry or Down Zero today, they are on these products because they don't want to sacrifice on the efficacy. And with an oral that actually showed the same level of efficacy, that becomes an argument to sway those patients to actually make the leap and go on to quick depend. So I think we've got a perfect profile to really appeal to all the different segments in the markets and make sure that ultimately this product becomes a leading product in prophylaxis.

Yanen Zhu Analyst — Wells Fargo

Great. That's very, very helpful. Way for us to think about the launch. Thanks for sharing that. But I do want to follow up on this long-acting injectable point you raised, right? But so how do we think about when that comes to market or perhaps also give us the sense of how far is that kind of product from the market?

Yeah, well as I said before and for sure there will be patients that will People prefer to have something that they do once and with very few infections, ideally, so six months is definitely the aim there, to be kind of lost of, I don't have to take a therapy. What people do forget, though, is by taking a long-acting injectable, you lose control, you lose flexibility. You basically have a drug in your system. And if you really want to wait till it's out of your body, you have to wait 18 months for a six-month injection. Take your half-life, it plays a role there. And that is something where what we try to offer with Decryptoban is people taking control of their lives. If you take that pill every morning or every evening on a daily basis, you know you should be protected. If you take a long-acting injectable, you kind of take a leap of faith. You inject yourself, and then you'll see at one point in time, you might run out of gas, I would say, and you might see breakthrough attacks happening. That might be before you actually hit the next injection. That is a model. That's an impact on the life of a patient, which is very challenging because, as you know, HE attacks are driven by stress. Or can be driven by stress. That kind of thinking is something that really is not conducive to avoiding or preventing attacks, and which is different, we believe, with a daily oral.

I mean, I think one reason that you see the high prevalence of injectables in the existing therapies is just also simply because of the challenges and difficulties of coming up with an orally available compound that is efficacious, so I think that, as I said in the beginning, I mean, with the correct amount, the first, to our knowledge, the first and only orally available beta receptor antagonist, but also, so far, also the only oral therapy with the level of efficacy that is comparable to the injectables.

Yanen Zhu Analyst — Wells Fargo

Definitely, definitely. So maybe can I ask you to comment on the pricing strategy for a prophylaxis setting?

Yeah, obviously we're not gonna disclose the price. We haven't decided on what the price will be. What you can say is that we will absolutely price to QuickJapan based on the value that it offers. Now, the pricing exercise for us will be a portfolio. Exercise. Because as you know, we have an on-demand product IR that we will be launching before the prophylaxis. So we will be looking in our pricing for the on-demand product at the whole portfolio. How can we make sure that we strike the optimal balance to ultimately maximize the impact of that product on our portfolio? And so we are... We are very gifted with the data we have on both fronts. We are not limited by anything. We can basically, we have all the flexibility, thanks to the quality of the data. So both in on-demand and in prophylaxis, we have stellar performance. Hence, we can really choose what type of pricing strategy we'll be following.

Yanen Zhu Analyst — Wells Fargo

Right, that's a great flexibility to have. Since we're on this topic, let's also touch on what is the implication of having the ability to offer both a on-demand option and also a prophylactic option? How can you leverage that to achieve best performance of the sales?

It's very interesting because I think it was about four or five years ago, there was a congress in Budapest, a very specialized congress in HE, that he wanted to be a workshop, and one of the doctors, we had results, I believe, from our on-demand phase two study at the time, and he got asked by his colleagues in the audience, he said, well, are you telling me that we would be using the same product for prophylaxis and on-demand? And he said, his answer was, isn't that what we were really dreaming of? Because that makes life so much easier. You basically have little, there's no uncertainty. You have the same molecule, the same product that can be used in both circumstances. And because the disease is threshold-driven, it's not, there's an escape mechanism or so. It's simply when you have, when you're on decryctivant prophylaxis and you have a breakthrough attack, it means you don't have enough drug, not enough decryctivant in your system to prevent the attack, to compete with bradycanin. So, basically, you top it up to mitigate the symptoms. That is... For the patient, an amazing thing, they have to deal with one specialty pharmacy, one company, they don't have to, if you have one company for your prophy and another one for your DT, there's two channels there. This makes it much easier. For the doctor, it makes it much easier, and potentially for the payer. And I think if you add to that on-demand prophy and the breadth of the label, we have the most complete solution for the community, which that ease that The simplicity will really help us commercially.

Peng Lu Other

And I also want to say that in the past that I was in the Humira team, that I also hope Ducretaban can also generate a similar halo effect. As Wayne just mentioned, when the treating physician considers Ducretaban, pretty much we can help the patients, no matter for on-demand or prophylaxis, type 1, type 2 patients or normal C1 patients with oral treatment. That's why we pretty much can help the physicians, help the patients with all the options they can consider. That's why, hopefully, once the physician knows the molecule there, they can handle the different scenarios, different cases.

Yanen Zhu Analyst — Wells Fargo

Great. Yeah, that's a great position to be in. So, as you just mentioned, On Demand will get to the market first. Indeed, with the PDUFA date of April 22nd, 23rd, 23rd rather, right, so wanted, obviously, the review has started, wanted to ask if you can comment on, you know, any color, the interaction with the agency so far, any potential focuses or concerns, and what do you, what could we expect to happen between Between now and April 23rd.

Peng Lu Other

Yeah, currently, as you know, we announced that currently we get the PDUFA data. We also submit the EU and the EMA validated. Regarding with the U.S., we expect very soon we get the metacycle review meeting with FDA, but currently that our interaction with FDA is, you know, is very as expected. You know, that we, so far we did not see much hurdle there for the approval, but as mentioned, once we have metacycle review, We will know more from agency.

Yanen Zhu Analyst — Wells Fargo

Got it, got it. Very, very helpful. In terms of label, is there anything for us to think about the label, or is it pretty much, for example, similar to X30's label?

Peng Lu Other

Excellent question. I want to highlight one thing that for the label, later on, I will hand it over to Wim why I want to highlight this point. Of course, compared to ACT-EARLY, we do feel that we have great ethics data, no matter from fast onset, right, that, you know, that's a complete resolution time. We, you know, compared to the fast onset that, you know, that for the, you know, that there's a time to the minimum, that improvement there, we only have 1.28 hours compared to the ACT-EARLY is pretty much around the two hours there. Under complete resolution, we can achieve less than 12 hours. Act early is over 24 hours. For single-dose use, only 17% of patients need a second dose compared to act early is close to 40%. All this is current label covered, but the most important we want to highlight that potentially maybe we have the novel endpoint covered in the label is time to end up progression. That this is a new endpoint. The team developed and validated there. And based on the physician and the patients, that's the first sign patients can feel that they get protection, the drug works, because it prevents the attack, get deteriorated. Our time to end our progression is only 17 minutes. That's correlated very well with the PK profile, so the fast absorption of our Ducre-Band that are capsules there. So this, that really, you know, to show that the Ducre-Band can help the patients by maintenance there, that the patient can feel the attack is well controlled.

Okay, yeah, and I think, Pong, you said, well, the real differentiator, when people ask me what is the differentiator for Ducre-Band IR, There's not one, it's the holistic management of the attack, from a rapid onset to complete resolution with a single capsule. That's really what's appealing, and it's very interesting. When we share this data recently with payers, they really, they're excited. They see the ability to really, you use the therapy, you're going to get to control very quickly, and you can do it with a single pill that has an economic impact on them, and so that is the full value proposition. As Pong was mentioning, we have endpoints, like in the progression, we'd love to have in the label, but that will be the team's negotiation to achieve that, but we will publish around these things, that information will be available, and it's something that the community, the physician community, is very excited about. They really recognize those outstanding results.

Yanen Zhu Analyst — Wells Fargo

Got it, got it. I clearly hear the differentiation there. There are many. But help us understand when you come PDUFA day, and maybe I'll ask you when can you launch right after PDUFA, or do you need some time to launch? But more importantly, how sticky the market is, right? Are we talking about you have to wait for all the new diagnosis of patients, or could there be switching?

I think it may also put the historic perspective on that. As I mentioned earlier, first came into the AGE space 23 years ago with the company that developed the Catibunt, And so having observed the new products that have come to this community over those two decades, what becomes very clear is that every new entrant has provided some additional benefit, be it either efficacy or motor administration, and the prophylactic segment, I think you could say, was established with the entrance of the texiro, reducing the injection frequency, making it feasible to have an injection. This is the injection that you work with prophylactically. The therapy that provides this incremental benefit always seems to take over, so what, and also the, I think, in our call that we had yesterday, Dr. Rydell also commented on that there is a high level of patient involvement in their decision-making and about which therapy, and there's a high awareness of what's out there, what's coming, and patients are looking to improve how they treat their condition. So, in our view, it's also what we see from data, it's not a sticky market, unlike maybe some other therapeutic areas. You look at switching, there's a constant churn of switching every quarter in the single digits, and every time there's a new product that comes to the market, it goes up to double digits because patients are eager to try the new and potentially the better product. So I think that that is a very dynamic space.

And the very interesting thing is everybody talks about it actorally, but by the time we launch... The lion's share of the patient will still be on the catibans. Fear is here. Now, those patients, they're going to see the quick demand as a trusted, validated mechanism. It's the same that they had before, but it doesn't come with the pain of the injection, which is... Really painful. And if you look at indirect treatment comparison, we probably have better data than ecataban. So we're going to be very aggressive going after those patients, and we anticipate there will be a wholesome switch from the ecataban segment into the crictaban, because it's the natural thing to do. And then for ectorily patients, There will be different effects. One will be the halo effect of the impact we have on the Akataban patients. If people see that these drugs work very well, people will say, oh, why don't I try? And we will work through a free trial program, a sampling program with our quick start program to give people the opportunity to try. And in on-demand, that's relatively straightforward. You can just try on the next attack and see how it works, and then you make your assessment. So I think we're in a very good position to win in this market. Again, with the addition of the normal C1 benefit mechanistically, broader ability to address a broader population. So I think we're very well armed to win there. Great.

Yanen Zhu Analyst — Wells Fargo

I think that's a great note, uh, to end this session on. Again, congrats on all the achievements and the great data, uh, reviewed yesterday. And, uh, thanks for your time.

Yeah. Thank you. Thank you for having us. Yeah.

Analyst Q&A · 1 question
Full-screen source Call document